About Leyden Labs
Leyden Laboratories B.V. (Leyden Labs) is a clinical-stage biotechnology company founded in 2020 and headquartered in Leiden, Netherlands. The company develops broadly protective intranasal nasal sprays that deliver antibodies directly to the nasal mucosa to prevent respiratory viruses, including influenza and coronaviruses, at their point of entry. Its lead program, PanFlu, uses the monoclonal antibody CR9114 licensed from Janssen Pharmaceuticals and is currently in clinical development for influenza prophylaxis.
Company details
Funding
Total raised
$336M
Last stage
Series B
Investors
Founders
Ronald Brus
Co-founder and Chief Business Officer of Leyden Labs.
Koenraad Wiedhaup
Former McKinsey & Company partner; co-founded Leyden Labs in 2020 alongside Jaap Goudsmit, Ronald Brus, and Dinko Valerio.
LinkedIn
Dinko Valerio
Biotech entrepreneur and former CEO of Crucell; also co-founded ProQR Therapeutics and Aescap Venture.
LinkedInJaap Goudsmit
Infectious disease scientist and former Chief Scientific Officer at Crucell; led the discovery of the CR9114 broadly-neutralizing influenza antibody.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.